• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物群代谢物在心血管疾病(CVD)发展中的重要性。

Importance of gut microbiota metabolites in the development of cardiovascular diseases (CVD).

机构信息

Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.

Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran.

出版信息

Life Sci. 2023 Sep 15;329:121947. doi: 10.1016/j.lfs.2023.121947. Epub 2023 Jul 16.

DOI:10.1016/j.lfs.2023.121947
PMID:37463653
Abstract

Cardiovascular disease (CVD) remains the most common cause of death worldwide and has become a public health concern. The proven notable risk factors for CVD are atherosclerosis, hypertension, diabetes, dyslipidemia, inflammation, and some genetic defects. However, research has shown a correlation between metabolic health, gut microbiota, and dietary risk factors. The gut microbiota makes an important contribution to human functional metabolic pathways by contributing enzymes that are not encoded by the human genome, for instance, the breakdown of polysaccharides, polyphenols and vitamins synthesis. TMAO and SCFAs, human gut microbiota compounds, have respective immunomodulatory and pro-inflammatory effects. Choline and l-carnitine are abundant in high-fat diets and are transformed into TMA by gut bacteria. The liver's phase of metabolism then changes TMA into TMAO. In turn, TMAO promotes the activation of macrophages, damages vascular endothelium, and results in CVD-however, dysbiosis decreases SCFAs and bile acids, which raises intestinal permeability. Congestion in the portal vein, a drop in cardiac output, a reduction in intestinal perfusion, and intestinal leakage are all caused by heart failure. These factors induce systemic inflammation by increasing intestinal leakage. By raising CRP and pro-inflammatory reactions, human gut dysbiosis and elevated TMAO levels promote the development of arterial plaque, hasten the beginning of atherosclerosis, and raise the risk of CAD. A healthy symbiosis between the gut microbiota and host is a key factor in shaping the biochemical profile of the diet, therefore which are crucial for maintaining the intestinal epithelial barrier, growing mucosa, reducing inflammation, and controlling blood pressure.

摘要

心血管疾病(CVD)仍然是全球最常见的死亡原因,已成为公共卫生关注的焦点。已证实的 CVD 显著危险因素包括动脉粥样硬化、高血压、糖尿病、血脂异常、炎症和一些遗传缺陷。然而,研究表明代谢健康、肠道微生物群和饮食风险因素之间存在相关性。肠道微生物群通过贡献人类基因组未编码的酶,为人类功能性代谢途径做出重要贡献,例如多糖、多酚和维生素的分解。TMAO 和 SCFAs 是人类肠道微生物群的化合物,分别具有免疫调节和促炎作用。胆碱和左旋肉碱在高脂肪饮食中含量丰富,被肠道细菌转化为 TMA。然后,肝脏的代谢阶段将 TMA 转化为 TMAO。反过来,TMAO 促进巨噬细胞的激活,损害血管内皮,导致 CVD-然而,肠道菌群失调会降低 SCFAs 和胆汁酸,从而增加肠道通透性。门静脉充血、心输出量下降、肠道灌注减少和肠漏都是心力衰竭引起的。这些因素通过增加肠道渗漏引起全身炎症。通过提高 CRP 和促炎反应,人类肠道菌群失调和 TMAO 水平升高会促进动脉斑块的发展,加速动脉粥样硬化的发生,并增加 CAD 的风险。肠道微生物群和宿主之间的健康共生是塑造饮食生化特征的关键因素,因此对于维持肠道上皮屏障、生长黏膜、减少炎症和控制血压至关重要。

相似文献

1
Importance of gut microbiota metabolites in the development of cardiovascular diseases (CVD).肠道微生物群代谢物在心血管疾病(CVD)发展中的重要性。
Life Sci. 2023 Sep 15;329:121947. doi: 10.1016/j.lfs.2023.121947. Epub 2023 Jul 16.
2
Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder.肠道微生物组及其在心血管疾病中的治疗干预作用。
Front Immunol. 2024 Jan 26;15:1321395. doi: 10.3389/fimmu.2024.1321395. eCollection 2024.
3
Role of Gut Microbiota and Their Metabolites on Atherosclerosis, Hypertension and Human Blood Platelet Function: A Review.肠道微生物群及其代谢产物在动脉粥样硬化、高血压和人类血小板功能中的作用:综述。
Nutrients. 2021 Jan 3;13(1):144. doi: 10.3390/nu13010144.
4
The Role of Gut Microbiota and Associated Compounds in Cardiovascular Health and its Therapeutic Implications.肠道微生物群及其相关化合物在心血管健康中的作用及其治疗意义。
Cardiovasc Hematol Agents Med Chem. 2024;22(3):375-389. doi: 10.2174/0118715257273506231208045308.
5
Gut Microbiota and Cardiovascular Disease: Symbiosis Versus Dysbiosis.肠道微生物群与心血管疾病:共生与失调。
Curr Med Chem. 2022;29(23):4050-4077. doi: 10.2174/0929867328666211213112949.
6
The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease.肠道微生物组和三甲胺氧化物在动脉粥样硬化和与年龄相关疾病中的作用。
Int J Mol Sci. 2023 Jan 25;24(3):2399. doi: 10.3390/ijms24032399.
7
Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide.肠道微生物群组成可调节饮食中胆碱的生物利用度以及促动脉粥样硬化代谢物氧化三甲胺的积累。
mBio. 2015 Mar 17;6(2):e02481. doi: 10.1128/mBio.02481-14.
8
Trimethylamine/Trimethylamine-N-Oxide as a Key Between Diet and Cardiovascular Diseases.三甲胺/氧化三甲胺:饮食与心血管疾病之间的关键因素
Cardiovasc Toxicol. 2021 Aug;21(8):593-604. doi: 10.1007/s12012-021-09656-z. Epub 2021 May 18.
9
Identification of TMAO-producer phenotype and host-diet-gut dysbiosis by carnitine challenge test in human and germ-free mice.通过肉碱挑战试验在人和无菌小鼠中鉴定 TMAO 产生表型和宿主-饮食-肠道失调。
Gut. 2019 Aug;68(8):1439-1449. doi: 10.1136/gutjnl-2018-317155. Epub 2018 Oct 30.
10
Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota.白藜芦醇通过重塑肠道微生物群调节氧化三甲胺(TMAO)合成和胆汁酸代谢,减轻TMAO诱导的动脉粥样硬化。
mBio. 2016 Apr 5;7(2):e02210-15. doi: 10.1128/mBio.02210-15.

引用本文的文献

1
Bridging the Gut Microbiota and the Brain, Kidney, and Cardiovascular Health: The Role of Probiotics.肠道微生物群与大脑、肾脏及心血管健康的关联:益生菌的作用
Probiotics Antimicrob Proteins. 2025 Sep 6. doi: 10.1007/s12602-025-10680-6.
2
Microbiome and cardiovascular health unexplored frontiers in precision cardiology: a narrative review.微生物群与心血管健康:精准心脏病学中未被探索的前沿领域:一篇综述。
Ann Med Surg (Lond). 2025 May 26;87(7):4255-4261. doi: 10.1097/MS9.0000000000003430. eCollection 2025 Jul.
3
Gut Microbiota and Bacterial Extracellular Vesicles: Emerging Roles in Myocardial Remodelling and Cardiac Health.
肠道微生物群与细菌细胞外囊泡:在心肌重塑和心脏健康中的新作用
J Extracell Biol. 2025 Aug 11;4(8):e70079. doi: 10.1002/jex2.70079. eCollection 2025 Aug.
4
Prognostic value of the lactate-to-albumin ratio in critically ill chronic heart failure patients with sepsis: insights from a retrospective cohort study.乳酸与白蛋白比值在合并脓毒症的重症慢性心力衰竭患者中的预后价值:一项回顾性队列研究的见解
Front Med (Lausanne). 2025 Jul 15;12:1593524. doi: 10.3389/fmed.2025.1593524. eCollection 2025.
5
Integrated Metabolomic and Gut Microbiome Profiles Reveal Postmortem Biomarkers of Fatal Anaphylaxis.综合代谢组学和肠道微生物组图谱揭示致命性过敏反应的死后生物标志物。
Int J Mol Sci. 2025 Jun 29;26(13):6292. doi: 10.3390/ijms26136292.
6
Association between serum short-chain fatty acid levels and the risk of all-cause and cardiovascular disease mortality in Chinese patients undergoing maintenance hemodialysis: a retrospective cohort study.中国维持性血液透析患者血清短链脂肪酸水平与全因及心血管疾病死亡风险的关联:一项回顾性队列研究
Clin Kidney J. 2025 May 29;18(6):sfaf168. doi: 10.1093/ckj/sfaf168. eCollection 2025 Jun.
7
Microbiota as diagnostic biomarkers: advancing early cancer detection and personalized therapeutic approaches through microbiome profiling.微生物群作为诊断生物标志物:通过微生物组分析推进早期癌症检测和个性化治疗方法。
Front Immunol. 2025 May 8;16:1559480. doi: 10.3389/fimmu.2025.1559480. eCollection 2025.
8
The role of microbiome dysbiosis in cardiovascular disease: Mechanisms and therapeutic implications.微生物群失调在心血管疾病中的作用:机制与治疗意义。
Glob Cardiol Sci Pract. 2025 Feb 28;2025(1):e202503. doi: 10.21542/gcsp.2025.3.
9
Advances in gut-lung axis research: clinical perspectives on pneumonia prevention and treatment.肠道-肺轴研究进展:肺炎防治的临床视角
Front Immunol. 2025 Apr 22;16:1576141. doi: 10.3389/fimmu.2025.1576141. eCollection 2025.
10
Association of dietary index of gut microbiota with cardiovascular disease risk: new evidence from NHANES 2007-2018.肠道微生物群饮食指数与心血管疾病风险的关联:来自2007 - 2018年美国国家健康与营养检查调查(NHANES)的新证据
BMC Cardiovasc Disord. 2025 Apr 28;25(1):332. doi: 10.1186/s12872-025-04776-8.